Dihydromyricetin activates AMP-activated protein kinase and P38MAPKexerting antitumor potential in osteosarcoma

Cancer Prevention Research

Volumn 7, Issue 9, 2014, Pages 927-938

  Zhao, Zhiqiang ^a   Yin, Jun Qiang ^a   Wu, Man Si ^b   Song, Guohui ^a   Xie, Xian Biao ^a   Zou, Changye ^a   Tang, Qinglian ^a   Wu, Yuanzhong ^b   Lu, Jinchang ^a   Wang, Yongqian ^a   Wang, Jin ^a   Kang, Tiebang ^b   Jia, Qiang ^c   Shen, Jingnan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUIZHOU ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; DIHYDROMYRICETIN; FLAVONOID; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H2AX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLAVONOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; OSTEOSARCOMA; OSTEOSARCOMA CELL; SIGNAL TRANSDUCTION; ANIMAL; BONE TUMOR; DRUG EFFECTS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; FLAVONOLS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; OSTEOSARCOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907287117     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0067     Document Type: Article

References (48)

1. BiermannJS, AdkinsDR,AgulnikM,BenjaminRS,Brigman B, Butrynski JE, et al. Bone cancer. J Natl Compr Cancer Netw 2013;11:688-723.
2. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr 2009;21:365-72.
3. Zhang Y, Que S, Yang X, Wang B, Qiao L, Zhao Y. Isolation and identification of metabolites from dihydromyricetin. Magn Reson Chem 2007;45:909-16.
4. Zhang YS, Ning ZX, Yang SZ, Wu H. Antioxidation properties and mechanism of action of dihydromyricetin from Ampelopsis grossedentata. Acta Pharmaceutica Sinica. 2003;38:241-4.
5. Shen Y, Lindemeyer AK, Gonzalez C, Shao XM, Spigelman I, Olsen RW, et al. Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci 2012;32:390-401.
6. Chen L, Wang C, Wei Q, Ning Z, Yuan E. Interaction of dihydromyricetin and alpha-amylase. Nat Prod Commun 2013;8: 339-42.
7. Chen T, Zhu S, Lu Y, Cao H, Zhao Y, Jiang G, et al. Probing the interaction of anti-cancer agent dihydromyricetin with human serum albumin: a typical method study. Anti-cancer Agents Med Chem. 2012;12:919-28.
8. Wu S, Liu B, Zhang Q, Liu J, Zhou W, Wang C, et al. Dihydromyricetin reduced Bcl-2 expression via p53 in human hepatoma HepG2 cells. PLoS ONE. 2013;8:e76886.
9. Zhou Fang-zhen HM, Zhang Xiao-yuan, Guo Yong. Synergy and Attenuation Effects of Dihydromyricetin on Tumor-Bearing Mice Affected by Breast Cancer Treated with Chemotherapy. J South China Univ Technol 2011;9:147-51.
10. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Bio 2012; 13:251-62.
11. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H. Cell cycle regulation via p53 phosphorylation by a 50-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophy Res Commun 2001;287:562-7.
12. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86.
13. Guo DL, Hildebrandt IJ, Prins RM, Soto H, MazzottaMM,Dang JL, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A 2009;106:12932-7.
14. Nilsson S, Huelsenbeck J, Fritz G. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. Cancer Lett 2011;304:60-9.
15. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. P38 (MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009;15:369-79.
16. Cuenda A, Rousseau S. P38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773:1358-75.
17. Cheng AW, Chan SL, Milhavet O, Wang SQ, Mattson MP. P38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells. J Biol Chem 2001;276:43320-7.
18. Hsu SS, Huang CJ, Cheng HH, Chou CT, Lee HY, Wang JL, et al. Anandamide-induced Ca2+ elevation leading to p38 MAPK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. Toxicology 2007;231:21-9.
19. Zou CY, Wang J, Shen JN, Huang G, Jin S, Yin JQ, et al. Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Acta Pharmacologica Sinica 2008;29:325-32.
20. Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett 2011;311:113-21.
21. Zhao ZQ, Wu MS, Zou CY, Tang QL, Lu JC, Liu DW, et al. Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-kappa B pathway. Cancer Lett 2014;342: 150-8.
22. Wu MS, Wang GF, Zhao ZQ, Liang Y, Wang HB, Wu MY, et al. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Mol Cancer Ther 2013;12: 1728-37.
23. Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, et al. Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst 2012; 104:749-63.
24. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
25. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21:245-55.
26. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
27. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012;31:2270-82.
28. Lee DH, Lee TH, Jung CH, Kim YH. Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells. Cell Signal 2012;24:2216-25.
29. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong ZF, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013;17:113-24.
30. Duo J, Ma YL, Wang GW, Han XX, Zhang C. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin A against osteosarcoma cell line. DNA Cell Biol 2013; 32:156-64.
31. Rocha GZ, DiasMM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, et al. Metformin amplifies chemotherapy-inducedAMPKactivation and antitumoral growth. Clin Cancer Res 2011;17:3993-4005.
32. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010;70:832-41.
33. WuXY, Zhong DX, Lin B, Zhai WL, Ding ZQ,WuJ. P38 MAPK regulates the expression of ether a go-go potassium channel in human osteosarcoma cells. Radiol Oncol 2013;47:42-9.
34. Hsu SS, Huang CJ, Cheng HH, Chou CT, Lee HY, Wang JL, et al. Anandamide-induced Ca2+ elevation leading to p38 MAPK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. Toxicology 2007;231:21-9.
35. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20:426-33.
36. Ji C, Yang B, Yang YL, He SH, Miao DS, He L, et al. Exogenous cellpermeable C6 ceramide sensitizes multiple cancer cell lines to doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010;29:6557-68.
37. Chen MB,WuXY, GuJH, Guo QT, Shen WX, Lu PH. Activation of AMPactivated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 2011;60:311-22.
38. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845-52.
39. Bacci G, Lari S. Current treatment of high grade osteosarcoma of the extremity: review. J Chemother 2001;13:235-43.
40. Frota MJ, Silva RB, Mothes B, Henriques AT, Moreira JC. Current status on natural products with antitumor activity from Brazilian marine sponges. Curr Pharm Biotechnol 2012;13:235-44.
41. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311-35.
42. He GX, Pei G, Zhou TD, Zhou XX. [Determination of total flavonoids and dihydromyricetin in Ampelopsis grossedentala (Hand-Mazz) W. T. Wang]. Zhongguo Zhong yao za zhi 1/4 Zhongguo zhongyao zazhi 1/4 China Journal of Chinese Materia Medica 2000;25:423-5.
43. He GX, Yang WL, Pei G, Zhu YH, Du FL. [Studies on the effect of dihydromyricetin on antilipid-peroxidation]. Zhongguo Zhong yao za zhi 1/4 Zhongguo zhongyao zazhi 1/4 China journal of Chinese materia medica. 2003;28:1188-90.
44. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
45. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDKinhibitor on PCNA-dependent DNAreplication and repair. Nature 1994;371:534-7.
46. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002;4:993-7.
47. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010;24:916-32.
48. Carling D, Mayer FV, Sanders MJ, Gamblin SJ. AMP-activated protein kinase: nature's energy sensor. Nat Chem Biol 2011;7:512-8.